Hall Render

NOVEMBER 30, 2023

On September 29, 2023, the Food and Drug Administration (“FDA”) announced the issuance of a Notice of Proposed Rulemaking (the “Proposed Rule”) to expand the FDA’s regulatory scope over in vitro diagnostics products (“IVDs”) to specifically address Laboratory Developed Tests (“LDTs”). Part 820 ), unless they fall under an exemption.

FDA 40

FDA Public Health Compliance Hospitals 40

Dot Compliance

JUNE 16, 2022

Maintaining compliance with safety and quality standards is a significant issue in medical device manufacturing. Millions of dollars are lost by manufacturers every year due to regulatory non-compliance issues and related lawsuits. We continuously hear of infractions and warnings issued to companies for lack of regulatory compliance.

FDA 52

FDA Regulatory Compliance Compliance Governance 52

Hall Render

JUNE 5, 2024

In April 2024, the Food and Drug Administration (“FDA”) issued a Final Rule amending the definition of in vitro diagnostics products (“IVDs”) found in 21 C.F.R. Stage 3: Effective May 6, 2027 Three years after the Final Rule’s publication, the FDA will enforce all remaining quality system requirements (under 21 C.F.R.

FDA 40

FDA Compliance Regulatory Compliance Licensing 40

Dot Compliance

JANUARY 14, 2022

between 2021, and 2028. There are many risk management regulations and compliance standards in the life sciences industry that must be followed to successfully maintain business operations and ensure the safety of staff and product users. FDA’s Safer Technologies Program (SteP) for Medical Devices. Source: [link].

Compliance 52

Compliance FDA Regulatory Compliance Governance 52

Healthcare IT Today

SEPTEMBER 12, 2023

A major justification for President Biden’s tax hike proposal is to shore up the tenuous finances of Medicare whose trust fund is forecasted to be depleted by 2028. Historically, it is the most prolific driver of family bankruptcy, and now it is on its way to bankrupting our country collectively.

Nurses 78

Nurses Doctors Medicare Medicare 78

Healthcare Law Blog

AUGUST 25, 2022

Fifteen more Part D drugs are set to be published in 2027, followed by 15 Part D and Part B drugs, collectively, in 2028. Drugs eligible for negotiation must be FDA-approved for at least 7 years and marketed in conformance with the Federal Food, Drug, and Cosmetic Act. Program Compliance. Negotiation-Eligible Drugs.

Medicare 52

Medicare Medicare Medicaid Medicaid 52

SQA

MAY 24, 2023

The vote occurred on 16 February 2023 following a plenary meeting of the European Parliament, and represents a significant step towards a formal extension of MDR and IVDR compliance deadlines for some device manufacturers.

FDA 40

FDA Licensing Governance Compliance 40